当前位置：
X-MOL 学术
›
J. Diabetes Investig.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Achieving the composite end-point of glycated hemoglobin <7.0% without weight gain or hypoglycemia with once-weekly dulaglutide in Chinese patients with type 2 diabetes: A post-hoc analysis.
Journal of Diabetes Investigation ( IF 3.2 ) Pub Date : 2020-01-03 , DOI: 10.1111/jdi.13187 Xinhua Xiao 1 , Changjiang Wang 2 , Xiaoyang Lai 3 , Bin Zhang 4 , Liqun Gu 4 , Jianing Hou 5 , Zhiguang Zhou 6
Journal of Diabetes Investigation ( IF 3.2 ) Pub Date : 2020-01-03 , DOI: 10.1111/jdi.13187 Xinhua Xiao 1 , Changjiang Wang 2 , Xiaoyang Lai 3 , Bin Zhang 4 , Liqun Gu 4 , Jianing Hou 5 , Zhiguang Zhou 6
Affiliation
|
To assess the effect of dulaglutide (DU) 1.5/0.75 mg in comparison with glimepiride (GLIM) or insulin glargine (GLAR) on the composite end‐point in Chinese type 2 diabetes patients.
更新日期：2020-01-03
京公网安备 11010802027423号